• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Acuren Corporation

    3/27/25 4:16:05 PM ET
    $TIC
    Get the next $TIC alert in real time by email
    S-8 1 ea0235468-s8_acuren.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on March 27, 2025

    Registration No. 333-          

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C.  20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Acuren Corporation

    (Exact name of registrant as specified in its charter)

     

    Delaware

      66-1076867
    (State or other jurisdiction of   (I.R.S. Employer Identification No.)
    incorporation or organization)    

     

    14434 Medical Complex Drive, Suite 100
    Tomball, Texas 77377
    (Address of Principal Executive Offices) (Zip Code)

      

    Acuren Corporation 2024 Equity Incentive Plan

    (Full title of the plan)

     

     

     

    Fiona Sutherland

    General Counsel and Corporate Secretary

    Acuren Corporation

    14434 Medical Complex Drive, Suite 100

    Tomball, Texas 77377

    (Name and address of agent for service)

     

    (800) 218-7450

    (Telephone number, including area code, of agent for service)

     

     

     

    Copy to:

     

    Flora R. Perez, Esq.

    Brian J. Gavsie, Esq.

    Greenberg Traurig, P.A.

    401 East Las Olas Boulevard Suite 2000

    Fort Lauderdale, FL 33301

    (954) 765-0500

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☐
      Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information specified in Part I of this Registration Statement will be delivered in accordance with Form S-8 and Rule 428(b) under the Securities Act of 1933, as amended (the “Securities Act”) to all persons who participate in the Acuren Corporation 2024 Equity Incentive Plan (the “Plan”). These documents are not required to be, and are not, filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following document(s), which have been filed with the Commission by Acuren Corporation, a Delaware corporation (the “Company”) are incorporated herein by reference, other than information furnished pursuant to Item 2.02 or Item 7.01, or related exhibits under Item 9.01, of Form 8-K:

     

    (1) The Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 27, 2025;

     

    (2) The description of the Company’s common stock contained in the Company’s Registration Statement on Form 8-A, filed with the Commission on February 14, 2025 (File No. 1-2524) and in Exhibit 4.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 27, 2025, and any amendment or report filed for the purpose of updating such description; and

     

    (3) The Company’s Current Reports on Form 8-K filed with the Commission on January 31, 2025, March 4, 2025 and March 27, 2025.

     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information furnished under Items 2.02 or Item 7.01, or related exhibits under Item 9.01, of Form 8-K, which information is not incorporated by reference herein) prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 4. DESCRIPTION OF SECURITIES

     

    Not applicable.

     

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

     

    None.

     

    II-1

     

     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

     

    Section 102(b)(7) of the DGCL permits a Delaware corporation, in its certificate of incorporation, to limit or eliminate the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breaches of fiduciary duty as a director, except for liability of (a) a director or officer for (i) any breach of the duty of loyalty to the corporation or its stockholders, (ii) acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or (iii) transactions from which such director or officer derived an improper personal benefit; (b) a director for the willful or negligent payment of unlawful dividends or purchases or redemptions of shares of stock; or (c) an officer in any action by or in the right of the corporation.

     

    Under Section 145 of the DGCL, a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation (or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. In the case of an action brought by or in the right of a corporation, the corporation may indemnify any person who was or is a party or is threatened to be made a party to any such threatened, pending or completed action by reason of the fact that the person is or was a director, officer, employee or agent of the corporation (or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) only against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification may be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent the appropriate court finds that, in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the court shall deem proper.

     

    As permitted by Section 102(b)(7) of the DGCL, the Company’s certificate of incorporation provides that no director or officer of the Company shall be liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director except to the extent that such exemption from liability or limitation thereof is not permitted under the DGCL as currently in effect or as the same may be amended. This provision in the Company’s certificate of incorporation will not eliminate the directors’ or officers’ fiduciary duties, and in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each director and officer of the Company may be subject to personal liability for (i) any breach of the duty of loyalty to the corporation or its stockholders, (ii) acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or (iii) transactions from which such director or officer derived an improper personal benefit; each director of the Company may be subject to personal liability for the willful or negligent payment of unlawful dividends or purchases or redemptions of shares of stock; and each officer of the Company may be subject to personal liability in any action by or in the right of the corporation. The provision also will not affect a director’s responsibilities under any other applicable law, such as the United States federal securities laws or state or federal environmental laws.

     

    The Company’s bylaws also provide that the Company is required to indemnify and advance expenses to its present and former officers and directors to the fullest extent permitted by applicable law.

     

    Further, effective July 30, 2024, the Company entered into director indemnification agreements pursuant to which it agreed to additional indemnification and advancement procedures and protections for its directors.

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

     

    Not applicable.

     

    II-2

     

     

    ITEM 8. EXHIBITS

     

    4.1   Specimen Common Stock certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form S-4 (File No. 333-282976), filed with the Commission on December 17, 2024).
    4.2   Specimen Series A Preferred Stock certificate (incorporated by reference to Exhibit 4.2 of the Registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form S-4 (File No. 333-282976), filed with the Commission on December 17, 2024).
    4.3   Amended and Restated Warrant Instrument, dated as of September 23, 2024, executed by Acuren Corporation (form of warrant contained in Schedule I thereto) (incorporated by reference to Exhibit 4.3 of the Registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form S-4 (File No. 333-282976), filed with the Commission on December 17, 2024).
    5.1   Legal Opinion of Greenberg Traurig.
    23.1   Consent of PricewaterhouseCoopers LLP (Successor).
    23.2   Consent of PricewaterhouseCoopers LLP (Predecessor).
    23.2   Consent of Greenberg Traurig, P.A. (included in Exhibit 5.1 hereto).
    24.1   Power of Attorney (included on the signature page hereto).
    99.1   Acuren Corporation 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form S-4 (File No. 333-282976), filed with the Commission on December 17, 2024).
    107   Filing Fee Table

     

    II-3

     

     

    ITEM 9. UNDERTAKINGS

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement;

     

      (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tomball, State of Texas, on the 27th day of March, 2025.

     

     

    ACUREN CORPORATION

       
      By: /s/ Talman Pizzey
      Name:  Talman Pizzey
      Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOWN TO ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Talman Pizzey, Kristin Schultes and Fiona E. Sutherland, his or her true and lawful attorney-in-fact and agent, each acting alone, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including any post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following person in the capacities indicated and on the date indicated below.

     

    Signature   Title   Date
             
    /s/ Talman Pizzey   President and Chief Executive Officer   March 27, 2025
    Talman Pizzey   (principal executive officer)    
             
    /s/ Kristin Schultes   Chief Financial Officer   March 27, 2025
    Kristin Schultes   (principal financial officer)    
             
    /s/ Gregory Conaway   Chief Accounting Officer   March 27, 2025
    Gregory Conaway   (principal accounting officer)    
             
    /s/ Sir Martin E. Franklin   Co-Chairman of the Board   March 27, 2025
    Sir Martin E. Franklin        
             
    /s/ Robert A. E. Franklin   Co-Chairman of the Board   March 27, 2025
    Robert A. E. Franklin        
             
    /s/ Antoinette C. Bush   Director   March 27, 2025
    Antoinette C. Bush        
             
    /s/ Rory Cullinan   Director   March 27, 2025
    Rory Cullinan        
             
    /s/ Elizabeth Meloy Hepding   Director   March 27, 2025
    Elizabeth Meloy Hepding        
             
    /s/ Peter Hochfelder   Director   March 27, 2025
    Peter Hochfelder        
             
    /s/ James E. Lillie   Director   March 27, 2025
    James E. Lillie        

     

    II-5

    Get the next $TIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TIC

    DatePrice TargetRatingAnalyst
    3/21/2025$13.00Neutral
    UBS
    More analyst ratings

    $TIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acuren Corporation Confirms Date for First Quarter 2025 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of critical asset integrity services, announced today that it intends to release its financial results for the three months ended March 31, 2025, before the market opens on Thursday, May 15, 2025. First Quarter Webcast and Conference Call Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, May 15, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. To listen to the call by telephone, please dial 877-407-0789 or 201-689-8562. Yo

      5/7/25 4:15:00 PM ET
      $TIC
    • Acuren Corporation Announces Results for the Fourth Quarter and Full Year 2024

      - Record full year revenue of $1.1 billion driven by deeper service line penetration with recurring customers, targeted new sales in key markets, and certain pricing initiatives - - Acuren has redomiciled in the U.S. and listed on NYSE American - - Establishes 2025 revenue outlook - Acuren Corporation (NYSE:TIC) ("Acuren" or the "Company"), a leading provider of critical asset integrity services, today reported its financial results for the three months and full year ended December 31, 2024. The presentation of our operating results reflects the Company's acquisition of ASP Acuren Holdings, Inc. ("ASP Acuren" or the "ASP Acuren Acquisition"). The period from July 30, 2024, through Decem

      3/27/25 7:00:00 AM ET
      $TIC
    • Acuren Corporation Confirms Date for Fourth Quarter and Full Year 2024 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of asset integrity services, announced today that it intends to release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, March 27, 2025. Webcast and Conference Call: Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday March 27, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. Additionally, a slide presentation will accompany the conference call. To listen to the call by tel

      3/24/25 7:15:00 AM ET
      $TIC

    $TIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF HUMAN RESOURCES OFFICER Gaucher Anthony

      4 - ACUREN CORP (0002032966) (Issuer)

      4/15/25 4:36:46 PM ET
      $TIC
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Pizzey Talman

      4 - ACUREN CORP (0002032966) (Issuer)

      4/15/25 4:30:08 PM ET
      $TIC
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Schultes Kristin B

      4 - ACUREN CORP (0002032966) (Issuer)

      4/15/25 4:30:06 PM ET
      $TIC

    $TIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Acuren Corporation with a new price target

      UBS initiated coverage of Acuren Corporation with a rating of Neutral and set a new price target of $13.00

      3/21/25 8:16:22 AM ET
      $TIC

    $TIC
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Acuren Corporation

      SCHEDULE 13G - ACUREN CORP (0002032966) (Subject)

      5/9/25 4:14:00 PM ET
      $TIC
    • SEC Form 424B3 filed by Acuren Corporation

      424B3 - ACUREN CORP (0002032966) (Filer)

      4/24/25 4:28:55 PM ET
      $TIC
    • Acuren Corporation filed SEC Form 8-K: Other Events

      8-K - ACUREN CORP (0002032966) (Filer)

      4/24/25 4:23:39 PM ET
      $TIC

    $TIC
    Financials

    Live finance-specific insights

    See more
    • Acuren Corporation Confirms Date for First Quarter 2025 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of critical asset integrity services, announced today that it intends to release its financial results for the three months ended March 31, 2025, before the market opens on Thursday, May 15, 2025. First Quarter Webcast and Conference Call Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, May 15, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. To listen to the call by telephone, please dial 877-407-0789 or 201-689-8562. Yo

      5/7/25 4:15:00 PM ET
      $TIC
    • Acuren Corporation Announces Results for the Fourth Quarter and Full Year 2024

      - Record full year revenue of $1.1 billion driven by deeper service line penetration with recurring customers, targeted new sales in key markets, and certain pricing initiatives - - Acuren has redomiciled in the U.S. and listed on NYSE American - - Establishes 2025 revenue outlook - Acuren Corporation (NYSE:TIC) ("Acuren" or the "Company"), a leading provider of critical asset integrity services, today reported its financial results for the three months and full year ended December 31, 2024. The presentation of our operating results reflects the Company's acquisition of ASP Acuren Holdings, Inc. ("ASP Acuren" or the "ASP Acuren Acquisition"). The period from July 30, 2024, through Decem

      3/27/25 7:00:00 AM ET
      $TIC
    • Acuren Corporation Confirms Date for Fourth Quarter and Full Year 2024 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of asset integrity services, announced today that it intends to release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, March 27, 2025. Webcast and Conference Call: Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday March 27, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. Additionally, a slide presentation will accompany the conference call. To listen to the call by tel

      3/24/25 7:15:00 AM ET
      $TIC